Compare VIK & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIK | DGX |
|---|---|---|
| Founded | 1997 | 1967 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3B | 23.1B |
| IPO Year | 2023 | 1996 |
| Metric | VIK | DGX |
|---|---|---|
| Price | $68.52 | $200.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 13 |
| Target Price | $78.08 | ★ $208.62 |
| AVG Volume (30 Days) | ★ 2.3M | 997.7K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | ★ 1.69% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 8.75 |
| Revenue | N/A | ★ $11,035,000,000.00 |
| Revenue This Year | $13.91 | $7.55 |
| Revenue Next Year | $13.06 | $3.75 |
| P/E Ratio | $37.68 | ★ $23.37 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $31.79 | $157.20 |
| 52 Week High | $81.48 | $213.50 |
| Indicator | VIK | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 37.83 | 47.99 |
| Support Level | $56.95 | $176.61 |
| Resistance Level | $74.58 | $213.35 |
| Average True Range (ATR) | 3.01 | 4.13 |
| MACD | -1.05 | -1.34 |
| Stochastic Oscillator | 3.91 | 3.28 |
Viking Holdings Ltd is a travel company, with a fleet of 92 small ships, which view as floating hotels. It offers travel experiences on all seven continents in all three categories of the cruise industry river, ocean, and expedition cruising. The Group defines its products based on the type of cruise offering and language of the cruise service. The River segment provides river cruises outside the United States to English-speaking passengers. The Ocean segment offers ocean cruises to English-speaking passengers. Other include operating segments that are not individually reportable, consisting of expedition cruises for English-speaking passengers (Expedition), Mississippi River cruises for English-speaking passengers, and Viking China, which includes cruises for Mandarin.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.